Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CRABP2 encodes a member of the retinoic acid (RA, a form of vitamin A) binding protein family and lipocalin/cytosolic fatty-acid binding protein family. Additionally we are shipping CRABP2 Kits (18) and CRABP2 Proteins (16) and many more products for this protein.
Showing 10 out of 161 products:
Human Monoclonal CRABP2 Primary Antibody for BI, WB - ABIN2689474
Lane, Xu, Wilen, Sylvester, Derguini, Gudas: LIF removal increases CRABPI and CRABPII transcripts in embryonic stem cells cultured in retinol or 4-oxoretinol. in Molecular and cellular endocrinology 2007
Show all 2 Pubmed References
Human Polyclonal CRABP2 Primary Antibody for ICC, IF - ABIN4300356
Seidensaal, Nollert, Feige, Muller, Fleming, Gunkel, Zaoui, Grabe, Weichert, Weber, Plinkert, Simon, Hess et al.: Impaired aldehyde dehydrogenase 1 subfamily member 2A-dependent retinoic acid signaling is related with a mesenchymal-like phenotype and an unfavorable prognosis of head and neck squamous cell ... in Molecular cancer 2015
Human Polyclonal CRABP2 Primary Antibody for ICC, IF - ABIN251030
Itoh, Ishikawa, Kitaguchi, Sato, Naito, Hashimoto: Development of target protein-selective degradation inducer for protein knockdown. in Bioorganic & medicinal chemistry 2011
Zebrafish Crabp2a and Crabp2b are essential for expression of hoxb4 (show HOXB4 Antibodies) and hoxb5 (show HOXB5 Antibodies) in the hindbrain.
Chromosome mapping of CRABP1 (show RBP1 Antibodies) AND CRABP2 in swine.
These data suggest a retinoic acid-independent, non-tumor suppressor role of CRABP2 for the survival of Malignant peripheral nerve sheath tumor (MPNST) cells in vitro. Targeting CRABP2 overexpression may represent a unique approach for the treatment of human MPNST.
A high expression ratio between FABP5 (show FABP5 Antibodies) and CRABPII may be related to CP tumor recurrence and ATRA could be a potential therapeutic agent for CP chemotherapy.
Holo-CRABPs had higher affinity for CYP26B1 (show CYP26B1 Antibodies) than free atRA, but both apo (show C9orf3 Antibodies)-CRABPs(CRABP-I (show CRABP1 Antibodies) and CRABP-II ) inhibited the formation of 4-OH-RA by CYP26B1 (show CYP26B1 Antibodies).
reducing CRABP2 levels may enhance the therapeutic index of Retinoic acid in glioblastoma multiforme patients
The anticarcinogenic activities of CRABP2 are mediated by both HuR (show ELAVL1 Antibodies) and RAR (show RARA Antibodies).
CBX3 (show CBX3 Antibodies) and CRABP2 expression was markedly increased in lung cancer tissues
we demonstrated significant changes in CRABP1 (show CRABP1 Antibodies) and CRABP2 expression in non-small cell lung cancer samples
Reengineering of cellular retinoic acid binding protein II (CRABPII) to be capable of binding retinal as a protonated Schiff base is described
CRABP2 controls mRNA stabilization by HuR (show ELAVL1 Antibodies).
Factors involved in the retinoid pathway, in particular upregulation of CRBP (show RBP1 Antibodies), CRABP1 (show CRABP1 Antibodies) and CRABP2, also showed differential expression in tumors with different histological subtypes
Results show that acetylation status of CRABPII directly influences embryonic stem cell differentiation in response to retinoic acid.
all three proteins (RDH10 (show RDH10 Antibodies), RALDH2 (show ALDH1A2 Antibodies), and CRABP2) appeared to be required for ATRA production induced by activation of PPARgamma (show PPARG Antibodies)
CRABP2 promotes myoblast differentiation and is modulated by the transcription factors MyoD (show MYOD1 Antibodies) and Sp1 (show SP1 Antibodies) in C2C12 cells.
observations emphasize the important role of CRABP-II in regulating the transcriptional activity of RA through RAR (show RARA Antibodies), and they demonstrate that repression of this gene is critical for allowing adipogenesis to proceed
Localization revealed epithelial-mesenchymal interactions, differentiation differences within the retinoic acid biosynthesis and signaling pathway, and observations on nuclear versus cytoplasmic locations of Crabp2 and RA receptors (alpha, beta, gamma).
Increases in CRABPI (show CRABP1 Antibodies) and II transcripts in the absence of leukemia inhibitory factor (show LIF Antibodies) may regulate aspects of embryonic stem cell differentiation in response to retinol.
TIS7 (show IFRD1 Antibodies) inhibits CRABP II expression during axonal regeneration, thereby modulating retinoic acid signalling. Hence, neurite initiation and branching are regulated by a negative feedback mechanism involving TIS7 (show IFRD1 Antibodies) and CRABP II.
This gene encodes a member of the retinoic acid (RA, a form of vitamin A) binding protein family and lipocalin/cytosolic fatty-acid binding protein family. The protein is a cytosol-to-nuclear shuttling protein, which facilitates RA binding to its cognate receptor complex and transfer to the nucleus. It is involved in the retinoid signaling pathway, and is associated with increased circulating low-density lipoprotein cholesterol. Alternatively spliced transcript variants encoding the same protein have been found for this gene.
cellular retinoic acid-binding protein 2
, cellular retinoic acid binding protein 2
, cellular retinoic acid-binding protein II
, cellular lipid-binding protein
, cellular retinoic acid binding protein II